Trial Profile
LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Orismilast (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors LEO Pharma
- 01 Apr 2023 Results (from two studies phase 1 and phase 2) assessing Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets published in the Journal of the European Academy of Dermatology and Venereology
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
- 14 Mar 2017 Status changed from recruiting to active, no longer recruiting.